Detalles de la búsqueda
1.
Rationale and design of the RAPID-WATER-FLOW trial: Radiolabeled perfusion to identify coronary artery disease using water to evaluate responses of myocardial FLOW.
J Nucl Cardiol
; 31: 101779, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215598
2.
A review on the fate of micro and nano plastics (MNPs) and their implication in regulating nutrient cycling in constructed wetland systems.
J Environ Manage
; 350: 119559, 2024 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38016236
3.
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
Ann Surg
; 274(1): e45-e53, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33030849
4.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Eur J Nucl Med Mol Imaging
; 48(1): 113-122, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32383093
5.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28076709
6.
Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.
Int J Mol Sci
; 21(23)2020 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33260535
7.
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases.
Neuroendocrinology
; 106(1): 74-88, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-28728155
8.
Investigating Fluorescent Organic-Matter Composition as a Key Predictor for Arsenic Mobility in Groundwater Aquifers.
Environ Sci Technol
; 52(22): 13027-13036, 2018 11 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30339396
9.
Water Recovery from Advanced Water Purification Facility Reverse Osmosis Concentrate by Photobiological Treatment Followed by Secondary Reverse Osmosis.
Environ Sci Technol
; 52(15): 8588-8595, 2018 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29916696
10.
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT.
Eur J Nucl Med Mol Imaging
; 43(5): 964-973, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26631238
11.
Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
Eur J Nucl Med Mol Imaging
; 42(8): 1223-30, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25822655
12.
Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.
Cancer Biother Radiopharm
; 2024 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38905126
13.
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors.
Recent Results Cancer Res
; 194: 379-84, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918770
14.
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Recent Results Cancer Res
; 194: 551-9, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918782
15.
High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.
Recent Results Cancer Res
; 194: 373-8, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918769
16.
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
Recent Results Cancer Res
; 194: 561-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918783
17.
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Recent Results Cancer Res
; 194: 519-36, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918780
18.
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
Clin Nucl Med
; 48(3): 221-227, 2023 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36723881
19.
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
J Nucl Med
; 63(8): 1199-1207, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887335
20.
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Diagnostics (Basel)
; 12(8)2022 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36010276